Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jiangsu Hengrui Pharmaceuticals
Biotech
GSK strengthens COPD offering via $12B biobucks Hengrui deal
Having scored approval for Nucala in COPD, GSK has signed a major $12 billion deal to strengthen the pharma’s offering for the respiratory condition.
James Waldron
Jul 28, 2025 4:36am
Hengrui's GLP-1/GIP agonist posts 18% weight loss in ph. 3 trial
Jul 15, 2025 9:17am
Merck & Co. pens $200M upfront deal for Hengrui med
Mar 25, 2025 9:10am
Kailera reports Zepbound-rivaling weight loss in obesity phase 2
Jan 13, 2025 10:20am
BeiGene, Brii and Ideaya ring in 2025 with deals
Jan 2, 2025 8:30am
Merck inks $169M PARP1 deal, escalating challenge to AstraZeneca
Oct 30, 2023 8:40am
